Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | ELANE | P08246 | 5/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3678626 | 0.83 | POLB (0.35) | POLBELANE | |
| SCHEMBL3676892 | 0.83 | ELANE (0.37) | POLBELANECHRM2CHRM4CHRM1 | |
| SCHEMBL3682344 | 0.83 | POLB (0.35) | POLB | |
| SCHEMBL3672829 | 0.80 | ALDH1A1 (0.36) | POLB | |
| SCHEMBL3681502 | 0.79 | CHRM2 (0.39) | POLBCHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL3684117 | 0.77 | NAAA (0.37) | ELANE | |
| SCHEMBL3677426 | 0.77 | TSHR (0.51) | POLB | |
| SCHEMBL3678849 | 0.77 | CHRM2 (0.41) | POLBELANECHRM2CHRM4CHRM1 | |
| SCHEMBL3676716 | 0.77 | POLB (0.39) | POLBELANE | |
| SCHEMBL9080425 | 0.77 | POLB (0.43) | POLBELANECHRM2CHRM4CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7741514-B2 | Catalyst comprising N-substituted cyclic imide compound and process for producing organic compound using the catalyst | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2010-06-22 | — | — | US | disclosed |
| US-20060281629-A1 | Catalyst comprising N-substituted cyclic imide compound and process for producing organic compound using the catalyst | ISHII YASUTAKA | 2006-12-14 | — | — | US | disclosed |
| US-7115541-B2 | Catalyst comprising n-substituted cyclic imides and processes for preparing organic compounds with the catalyst | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2006-10-03 | — | — | US | disclosed |
| EP-1338336-A1 | CATALYSTS COMPRISING N-SUBSTITUTED CYCLIC IMIDES AND PROCESSES FOR PREPARING ORGANIC COMPOUNDS WITH THE CATALYSTS | Daicel Chemical Industries, Ltd. (JP) | 2003-08-27 | — | — | EP | disclosed |
| US-20030013603-A1 | Catalyst comprising n-substituted cylic imides and processes for preparing organic compounds with the catalyst | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2003-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281629-A1 | Catalyst comprising N-substituted cyclic imide compound and process for producing organic compound using the catalyst | NOS2, NOS1, NOS3 | POLB 2011/4885ELANE 2125/4885CHRM2 268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.